Axiom International Investors LLC DE lifted its stake in Medpace Holdings Inc (NASDAQ:MEDP) by 12.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,070 shares of the company’s stock after acquiring an additional 6,620 shares during the period. Axiom International Investors LLC DE’s holdings in Medpace were worth $3,659,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP raised its position in shares of Medpace by 11.2% in the third quarter. GSA Capital Partners LLP now owns 94,720 shares of the company’s stock worth $5,675,000 after buying an additional 9,520 shares in the last quarter. United Services Automobile Association purchased a new stake in shares of Medpace in the third quarter worth $302,000. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Medpace in the third quarter worth $37,292,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Medpace by 641.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 121,671 shares of the company’s stock worth $7,289,000 after buying an additional 105,271 shares in the last quarter. Finally, Tavio Capital LLC purchased a new stake in shares of Medpace in the third quarter worth $5,192,000. 53.90% of the stock is owned by hedge funds and other institutional investors.
In other Medpace news, CEO August J. Troendle sold 38,640 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $58.36, for a total transaction of $2,255,030.40. Following the sale, the chief executive officer now owns 351,851 shares in the company, valued at $20,534,024.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc sold 61,141 shares of the firm’s stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total value of $3,680,688.20. Following the sale, the insider now owns 9,084,369 shares in the company, valued at approximately $546,879,013.80. The disclosure for this sale can be found here. Insiders have sold 396,559 shares of company stock worth $23,422,389 in the last 90 days. Company insiders own 29.50% of the company’s stock.
Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.04. Medpace had a return on equity of 15.86% and a net margin of 10.84%. The business had revenue of $179.00 million for the quarter, compared to the consensus estimate of $175.07 million. During the same quarter last year, the business posted $0.40 earnings per share. The company’s revenue for the quarter was up 44.4% on a year-over-year basis. On average, analysts predict that Medpace Holdings Inc will post 2.51 EPS for the current fiscal year.
MEDP has been the topic of a number of recent analyst reports. SunTrust Banks upgraded Medpace from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a research report on Wednesday, October 31st. They noted that the move was a valuation call. TheStreet upgraded Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th. Finally, Zacks Investment Research upgraded Medpace from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research report on Thursday, November 1st. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $44.43.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Why do earnings reports matter?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.